PA Media on MSN1d
GSK lifts long-term sales targets on new drug pipeline
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
FTSE 100 movers: GSK surges on guidance; DCC in the red
Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...
London midday: Stocks slightly higher; GSK jumps on guidance upgrade
London stocks were still a touch higher by midday on Wednesday as investors continued to mull the impact of Trump’s trade war ...
GSK Stock Up On Q4 Results, Positive Outlook; Plans To Buyback GBP 2 Bln Shares
Shares of GSK Plc. were gaining around 6 percent on the London Stock Exchange, as well as in the pre-market activity on the NYSE, ...
LONDON BRIEFING: GSK hails pipeline as ups 2031 sales target
Mike Ralston, CEO of Blencowe Resources (BRES) and Manuel Pablo Zúñiga-Pflücker, President and CEO of PetroTal (PTAL) will be presenting and taking live Q&A at focusIR's Investor Webinar on Tuesday ...
GSK Lifts Long-Term Outlook on Drug Pipeline, Buys Back Shares
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
LONDON MARKET OPEN: GSK adds impetus but FTSE 100 struggles
The Shanghai Composite fell 0.7% in afternoon trade. It was the first time the Shanghai market re-opened after the Chinese New Year break. The Hang Seng Index in Hong Kong was down 0.9%. Tokyo's ...
FTSE 100 giant GSK eyes more than £40bn in sales by 2031
Pharmaceutical giant GSK has hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than ...
GSK boosts 2031 revenue target to over £40bn following robust Q4 results
The pharma giant hiked its 2031 sales forecast to more than £40bn, up from £38bn, after reporting better than forecast fourth ...
European markets open mixed ahead of more earnings reports; GSK up 6%
European markets opened mixed on Wednesday, with investors looking ahead to more earnings from a number of key companies.
Macau Business1d
GSK sees annual profit slide on Zantac drug fallout
British pharmaceutical group GSK on Wednesday reported a near halving of net profit in 2024 after settling hefty US lawsuits over its Zantac heartburn drug.
GSK raises long-term guidance, announces buybacks
GSK shares added ~6% in London trading on Wednesday after the British drugmaker lifted its 2031 outlook and announced a new share buyback program alongside better-than-expected earnings for Q4 2025.